KLĀRITOS has built three differentiated products: K-360, Klari PDP, and KlariPay. Our customers are employers, pension funds, government payers, biopharma companies, and diagnostic companies.
K-360 This is a multi-sided, managed-care platform with market-making capabilities. All features of K-360 platform are theragnostics-guided, connecting multiple products and users. Its digital health architecture provides a fully integrated distribution, payment, and treatment model (e.g., in rheumatoid arthritis).
K-360 eliminates the need for external PBMs and specialty pharmacies. It provides product differentiation and market enrichment features for the drugs available in its formulary. Furthermore, it provides digital specialty provider capabilities by offering disease & therapy management.
Klari PDP It is a disease-specific prescription drug plan (PDP) consisting of theragnostic-guided drug formularies. Rheumatoid arthritis (RA) is our first disease focus. These PDPs are offered to health-plan sponsors: employers, pension funds, and government payers. These PDPs provide both efficacy and financial assurances.
KlariPay It is a disease-specific assurance product offered through K-360 to health-plan sponsors. It provides two theragnostic-guided guarantees that are both patient-specific and population-based.
Efficacy Assurance is an a priori guarantee of achieving clinical remission or excellent response in patients. Thus, our approach fundamentally strives to transform the treatment paradigm: achieving disease remission or excellent response in a significant majority of treated patients.
Financial Assurance is an a priori limited money-back guarantee to health-plan sponsors if the therapy does not provide a desired therapeutic outcome within a defined period. For instance, in RA, this guarantee equates to the co-insurance amount.
Value Proposition Our internal analyses demonstrate that significant efficiencies can be achieved across the entire healthcare system, both on a patient-specific and population-based basis. For instance, in RA, we can achieve: (1) enhanced therapeutic efficacy in 1-2x or more patients; (2) reduced spending in unnecessary specialty drugs by (at least) 35%; (3) reduced direct medical cost by 25-35%; (4) Patient Therapeutic adherence (PTA) of 90% or above.
This managed-care model adopts precision medicine approach by integrating theragnostics in:
--Drug Reimbursement Contracts
--Drug Formulary Design
--Disease & Therapy Management